title: Allergic contact dermatitis to pimecrolimus.
abstract: Pimecrolimus suppresses the proinflammatory cytokine production of cutaneous T and mast cells (1). It is used to treat atopic dermatitis and is the active ingredient in the topical formulation pimecrolimus 1.0% cream (Elidel, Novartis Pharma AG, Basel, Switzerland).
authors.affiliation: School of Osteopathic Medicine, University of Medicine and Dentistry of New Jersey, Stratford 08024, NJ, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Saitta
authors.forename: Ronald
authors.initials: R
authors.lastname: Brancaccio
mesh_terms: D000368:Aged; D017449:Dermatitis, Allergic Contact / Q000209:etiology*; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus